Page last updated: 2024-10-27

fluconazole and Sarcoidosis, Pulmonary

fluconazole has been researched along with Sarcoidosis, Pulmonary in 1 studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Sarcoidosis, Pulmonary: Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhou, B1
She, J1
Yang, L1
Zhu, B1

Reviews

1 review available for fluconazole and Sarcoidosis, Pulmonary

ArticleYear
Coexistent pulmonary cryptococcal infection and pulmonary sarcoidosis: a case report and literature review.
    The Journal of international medical research, 2020, Volume: 48, Issue:2

    Topics: Adult; Biopsy; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cryptococcosis; Cryptococcus neoformans;

2020